Metastatic BRCA-Negative Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management

Featuring an interview with Prof Peter Schmid, including the following topics:

• Response to immunotherapy in breast cancer subtypes (0:00)
• Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51)
• Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03)
• ADC structure and treatment-related adverse events (19:02)
• Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06)
• Novel ADCs and bispecific antibodies under investigation for mBC (28:30)
• Comparing datopotamab deruxtecan and sacituzumab govitecan for HR-positive disease (33:01)
• Clinical investigator perspectives on the Phase III DESTINY-Breast09 trial evaluating first-line trastuzumab deruxtecan with or without pertuzumab versus THP (docetaxel/rastuzumab/pertuzumab) for HER2-positive mBC (35:06)

CME information and select publications